CXCL13 as a Predictive Biomarker for Response to Methotrexate Monotherapy in Rheumatoid Arthritis

Area of Science:

• Rheumatology
• Immunology
• Biomarker Discovery

Background:

• Early rheumatoid arthritis (RA) management requires effective prediction of treatment response.
• Methotrexate is a common first-line therapy for RA.
• Identifying reliable biomarkers to guide methotrexate treatment is crucial.

Purpose of the Study:

• To investigate the utility of baseline CXCL13 levels in predicting methotrexate response in early RA patients.
• To assess the role of CXCL13 in monitoring disease activity during methotrexate therapy.
• To evaluate CXCL13 as a potential biomarker for personalized RA treatment strategies.

Main Methods:

• Prospective study of 50 treatment-naive early RA patients.
• Categorization into methotrexate responders (MTX-R) and nonresponders (MTX-NR) at 12 weeks.
• Analysis of baseline and posttreatment CXCL13 levels and correlation with disease activity scores (DAS-28).

Main Results:

• Significantly higher baseline CXCL13 levels were observed in MTX-R compared to MTX-NR (P = 0.035).
• A baseline CXCL13 cutoff >100 pg/mL predicted methotrexate response with 62% accuracy.
• CXCL13 levels decreased significantly in MTX-R posttreatment (P < 0.001) but remained unchanged in MTX-NR.

Conclusions:

• Baseline CXCL13 levels may help stratify early RA patients likely to respond to methotrexate.
• Decreases in CXCL13 posttreatment correlate with clinical improvement, supporting its use in monitoring.
• CXCL13 shows potential as an adjunct biomarker for optimizing personalized RA therapy, warranting further validation.